Unravelling Cancer Genetics: Key Mechanisms, Hereditary Syndromes, and Therapeutic Advances | Chapter 7 | Achievements and Challenges of Medicine and Medical Science Vol. 5

 

Background: The field of cancer genetics has experienced unprecedented advancements over the past few decades, transforming the understanding of cancer biology and revolutionizing therapeutic approaches. This review aims to synthesize recent developments in cancer genetics, highlighting key discoveries, technological innovations, and their implications for precision oncology.

Methods: An extensive literature search was conducted, focusing on studies published in reputable journals. Key areas explored include the genetic basis of cancer, advances in genomic technologies, major cancer genomics projects, integration of genomics in therapeutics, immunotherapy, liquid biopsies, and the challenges and future directions in the field.

Results: Significant progress has been made in identifying oncogenes, tumor suppressor genes, and DNA repair mechanisms that drive cancer initiation and progression. Technological innovations such as next-generation sequencing, single-cell sequencing, and CRISPR-Cas9 genome editing have enabled comprehensive analyses of cancer genomes and functional validation of genetic alterations. Large-scale projects like The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) have provided invaluable genomic data resources. Integration of genomics into therapeutics has led to the development of targeted therapies and immunotherapies, improving patient outcomes. Liquid biopsies utilizing circulating tumor DNA offer non-invasive diagnostic and monitoring tools. However, challenges such as tumor heterogeneity, drug resistance, data integration, and ethical considerations persist.

Conclusion: Advances in cancer genetics have significantly enhanced our understanding of the molecular mechanisms underlying cancer and have led to the development of personalized therapeutic strategies. Ongoing research and technological innovations are essential to address current challenges and to further improve cancer prevention, detection, and treatment.

 

Author(s)details:-

 

Dr. Nandhini Balunathan, Ph.D (Assistant Professor [Human Genetics])
Department of Human Genetics, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), No.1 Ramachandra Nagar, Porur, Chennai - 600 116, Tamil Nadu, India.

 

Please See the book here :-  https://doi.org/10.9734/bpi/acmms/v5/3594

Personalized Treatment of Rare Cancers Based on Comprehensive Diagnostics: Case Reports of Two Neuroendocrine Breast Cancers | Chapter 11 | Current Innovations in Medicine and Medical Science Vol. 4

 The current case study highlights the diagnostic and treatment difficulties that two patients with NEBC experienced throughout their epicrisis in the aforementioned circumstances. One percent of all neuroendocrine tumours and 0.1% of all breast carcinomas are caused by the rare disease known as neuroendocrine breast cancer (NEBC) [6]. Here, we offer two case reports of NEBC cohorts with large cell and small cell diagnoses in the absence of prospective trial data. When the first treatments failed, thorough tumour profiling was used to produce tailored treatment plans for both patients. Targetable changes of the PI3K/AKT/mTOR pathway, including a PIK3CA mutation and a STK11 mutation that inhibits the mTOR complex, were discovered in both individuals. The two patients' epicrisis serves as an example of how to manage rare and challenging cancers and how modern diagnostic techniques support medical management. The earlier we consider adopting customised medicines based on thorough tumour features, the sooner we can determine whether this strategy will be beneficial. Trials focused on a variety of uncommon cancer types and thorough profiling may contain the secret to an effective cure.

Author(s) Details:

Dörthe Schaffrin-Nabe,
Praxis für Hämatologie und Onkologie, Bochum, Germany.

Anke Josten-Nabe,
Praxis für Hämatologie und Onkologie, Bochum, Germany.

Stefan Schuster,
Datar Cancer Genetics Europe GmbH, Eckersdorf, Germany.

Andrea Tannapfel,
Institute of Pathology, Ruhr-University Bochum, Bochum, Germany.

Rudolf Voigtmann,
Praxis für Hämatologie und Onkologie, Bochum, Germany.

Please see the link here: https://stm.bookpi.org/CIMMS-V4/article/view/8401